Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.

According to Rolfo, in a time where liquid biopsies and biomarkers are being developed for the treatment of patients with lung cancer, clinical trials are invaluable. Additionally, conferences such as IASLC are important in bridging communication between the various markets of development, specifically North American, European, and Asian.

Although competitors in the marketplace, Rolfo says that as a community, oncologists must be more proactive networkers and should develop a more positive attitude in working together across borders, as the only way to improve participation in clinical trials is to reach as many potential patients as possible.

Christian Rolfo, MD, PhD

Articles

Dr. Rolfo on Precision Medicine in Lung Cancer